Blueprint Medicines
Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases
June 3, 2025Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases
Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
Roche and Blueprint extend collaboration with $1.7 billion cancer drug development and commercialisation deal
July 14, 2020Manufacturing and Production, Research and Development Blueprint Medicines, Cancer, Roche, pralsetinib
Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib …
US approval for Blueprint Medicines’ gastrointestinal stromal tumour therapy
January 10, 2020Medical Communications, Sales and Marketing Ayvakit, Blueprint Medicines, Cancer, pharma
The FDA has moved to authorise Blueprint Medicines’ kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal …
Blueprint Medicines agrees $1 billion-plus deal with Roche for cancer therapy
March 16, 2016Business Services, Research and Development, Sales and Marketing Blueprint Medicines, Deals, Immunokinases, Roche, drug development
Blueprint Medicines Corp (Nasdaq: BPMC) said it has signed an over $1 billion deal with oncology drug giant Roche (SIX: ROG) …
